Literature DB >> 18073475

Prognostic value of natriuretic peptides in Chagas' disease: a 3-year follow-up investigation.

Maria da Consolação V Moreira1, Silvia Heringer-Walther, Niels Wessel, Tiago Moreira Ventura, Yong Wang, Heinz-Peter Schultheiss, Thomas Walther.   

Abstract

BACKGROUND: Chagas' disease (CD) affects around 18 million people in Latin America. To determine the diagnostic and prognostic value of natriuretic peptides in patients with CD, we measured atrial (ANP) and brain natriuretic peptide (BNP), and compared the findings with other dilated cardiomyopathies (DCM).
METHODS: Blood samples were obtained from 111 CD patients, 62 patients with DCM due to other causes, and 43 gender- and age-matched healthy subjects. The CD and DCM patients were subdivided according to their NYHA classification. Natriuretic peptide concentrations were determined by immunoradiometric assays.
RESULTS: ANP and more pronounced BNP levels were increased in CD and DCM patients in relation to the NYHA class. Circulating BNP concentrations were higher in CD patients in NYHA classes I-II than in the corresponding DCM patients (p = 0.020). Importantly, ANP and BNP were already significantly elevated in CD patients without systolic ventricular dysfunction (p < or = 0.001). In CD patients, both peptides were highly correlated with echocardiographic parameters (p < 10(-14)). Both ANP and BNP had comparable ability to predict death or the necessity for heart transplant (p < 0.0001).
CONCLUSION: Natriuretic peptide levels can be used as a marker of asymptomatic CD without ventricular dysfunction and thus could be an ideal tool to identify these patients for early therapy. (c) 2007 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18073475     DOI: 10.1159/000112403

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  5 in total

Review 1.  Chronic Chagas' heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine.

Authors:  Silvia Gilka Muñoz-Saravia; Annekathrin Haberland; Gerd Wallukat; Ingolf Schimke
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

2.  Prognosis of chronic Chagas heart disease and other pending clinical challenges.

Authors:  Rosália Morais Torres; Dalmo Correia; Maria do Carmo Pereira Nunes; Walderez O Dutra; André Talvani; Andréa Silvestre Sousa; Fernanda de Souza Nogueira Sardinha Mendes; Maurício Ibrahim Scanavacca; Cristiano Pisani; Maria da Consolação Vieira Moreira; Dilma do Socorro Moraes de Souza; Wilson de Oliveira Junior; Silvia Marinho Martins; João Carlos Pinto Dias
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-06-06       Impact factor: 2.747

3.  Chagas cardiomyopathy: the potential of diastolic dysfunction and brain natriuretic peptide in the early identification of cardiac damage.

Authors:  Ana Garcia-Alvarez; Marta Sitges; María-Jesús Pinazo; Ander Regueiro-Cueva; Elizabeth Posada; Silvia Poyatos; José Tomás Ortiz-Pérez; Magda Heras; Manel Azqueta; Joaquim Gascon; Ginés Sanz
Journal:  PLoS Negl Trop Dis       Date:  2010-09-21

Review 4.  Biomarkers of therapeutic responses in chronic Chagas disease: state of the art and future perspectives.

Authors:  Maria-Jesus Pinazo; Maria-Carmen Thomas; Juan Bustamante; Igor Correia de Almeida; Manuel-Carlos Lopez; Joaquim Gascon
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-04-28       Impact factor: 2.743

5.  Measurement of multiple cytokines for discrimination and risk stratification in patients with Chagas' disease and idiopathic dilated cardiomyopathy.

Authors:  Yong Wang; Niels Wessel; Franziska Kohse; Adnan Khan; Heinz-Peter Schultheiss; Maria da Consolaҫão V Moreira; Thomas Walther
Journal:  PLoS Negl Trop Dis       Date:  2021-03-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.